Chemistry: analytical and immunological testing – Process or composition for determination of physical state... – By thermoparticulating composition
Reexamination Certificate
2007-01-23
2007-01-23
Le, Long V. (Department: 1641)
Chemistry: analytical and immunological testing
Process or composition for determination of physical state...
By thermoparticulating composition
C435S007100, C435S007200, C435S007210, C435S007920, C435S007930, C435S007940, C435S007950, C435S007900, C435S967000, C435S973000, C436S540000, C436S546000, C436S548000, C436S013000, C436S015000, C436S071000, C436S517000, C436S819000
Reexamination Certificate
active
10174797
ABSTRACT:
A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams/deciliter.
REFERENCES:
patent: 5024829 (1991-06-01), Berger et al.
patent: 5026537 (1991-06-01), Daddona et al.
patent: 5046499 (1991-09-01), Berger
patent: 5120834 (1992-06-01), Gargan et al.
patent: 5196324 (1993-03-01), Bumol et al.
patent: 5223410 (1993-06-01), Gargan et al.
patent: 5362649 (1994-11-01), Schwertner
patent: 5380667 (1995-01-01), Schwertner
patent: 5396886 (1995-03-01), Cuypers
patent: 5453359 (1995-09-01), Gargan et al.
patent: 5487892 (1996-01-01), Gargan
patent: 5597726 (1997-01-01), Bumol et al.
patent: 5604105 (1997-02-01), Jackowski
patent: 5658729 (1997-08-01), Hayden
patent: 5690103 (1997-11-01), Groth et al.
patent: 5710008 (1998-01-01), Jackowski
patent: 5756067 (1998-05-01), Redgrave et al.
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6309888 (2001-10-01), Holvoet et al.
patent: 6727102 (2004-04-01), Holvoet et al.
patent: 2003/0100486 (2003-05-01), Ridker et al.
patent: 2003/0152566 (2003-08-01), Schonbeck et al.
patent: 0 327 418 (1989-08-01), None
patent: 0 484 863 (1992-05-01), None
patent: 0 433 088 (1997-06-01), None
patent: 4-173096 (1992-06-01), None
patent: 8-304395 (1996-11-01), None
patent: 9-5323 (1997-10-01), None
patent: WO 94/23302 (1994-10-01), None
patent: PCT/EP97/03287 (1997-06-01), None
patent: PCT/EP97/03493 (1997-07-01), None
patent: WO 98/59248 (1998-12-01), None
Brody, JE. “Hunt For Heart Disease Tracks A New Suspect.”The New York Times. 3 pages (Jan. 6, 2004).
Chapelle JP. “How Should We proceed When A Myocardial Infarction Is Suspected,”Acta Clinica Belgica1984; 39(6): 393-395.
Hirschfield GM, Pepys MB. “C-reactive protein and cardiovascular disease: new insights from an old molecule.”Q J Med.Nov. 2003; 96(11): 793-807.
Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F. “Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.”Arterioscler Thromb Vasc Biol.May 2001; 21(5): 844-848.
Holvoet P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM, Simonsick EM, Colbert LH, Kritchevsky SB. “Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study.”Arterioscler Thromb Vasc Biol.Aug. 2003; 23(8): 1444-1448.
Hulthe J, Fagerberg B. “Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study).”Arterioscler Thromb Vasc Biol.Jul. 1, 2002; 22(7):1162-1167.
Lee TH, Goldman L. Serum Enzymes In The Diagnosis Of Acute Myocardial Infarction,Annals of Internal Medicine1986; 105: 221-223.
Major AS, Dove DE, Ishiguro H, Su YR , Brown AM, Liu L, Carter KJ, Linton MF, Fazio S. “Increased Cholesterol Efflux In Apolipoprotein AI (ApoAI)-Producing Macrophages As A Mechanism For Reduced Atherosclerosis In ApoAI((-/-)) mice.”Arterioscler Thromb Vasc Biol.Nov. 2001; 21(11): 1790-1795.
Ridker PM, Glynn, RJ, Hennekens, CH. “C-Reactive Protein Adds To The Predictive Value Of Total And HDL Cholesterol In Determining Risk Of First Myocardial Infarction.”Circulation1998; 97:2007-2011.
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. “Prospective Study Of C-Reactive Protein And The Risk Of Future Cardiovascular Events In Stable And Unstable Angina.”Circulation1998; 98:731-733.
Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, Robbie L, Ganz P, Kinlay S, Libby P. “Oxidized Low-Density Lipoprotein Augments And 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40I Expression In Human Vascular Cells.”Circulation2002; 106(23): 2888-2893.
Shacter E. “Quantification And Significance Of Protein Oxidation In Biological Samples.”Drug Metab Rev.Aug.-Nov. 2000; 32(3-4): 307-26.
Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U. “Soluble CD40L: Risk Prediction After Acute Coronary Syndromes.”Circulation2003; 108(9): 1049-1052.
Wentworth P Jr, Nieva J, Takeuchi C, Galve R, Wentworth AD, Dilley RB, DeLaria GA, Saven A, Babior BM, Janda KD, Eschenmoser A, Lerner RA. “Evidence for ozone formation in human atherosclerotic arteries.”Science2003; 302(5647): 1053-1056.
Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB. “The Metabolic Syndrome, Circulating Oxidized LDL, And Risk of Myocardial Infarction In Well-Functioning Elderly People In The Health, Aging, And Body Composition Cohort.”Diabetes.2004; 53(4): 1068-1073.
Sigurdardottir V, Fagerberg B, Hulthe J. “Circulating Oxidized Low-Density Lipoprotein (LDL) Is Associated With Risk Factors of The Metabolic Syndrome And LDL Size in Clinically Healthy 58-Year-Old Men (AIR Study).”J Intern Med.2002; 252(5): 440-447.
Adams JE, 3d, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS. “Cardiac Troponin I. A Marker With High Specificity For Cardiac Injury,”Circulation. 1993; 88(1): 101-106.
American Biogenetic Sciences Inc. 1995Annual Report.24 pages (1995).
American Biogenetic Sciences. Focus on Diagnostic Tests: A Technology Analysis. Updated Full Report.33 pages. Paisley and Habermas, Inc. (Jun. 3, 1996).
American Biogenetic Sciences, Inc., “Renal dialysis joint venture announced by American Biogenetic Sciences, Inc. and Gull Laboratories, Inc.” News Release (Sep. 26, 1996).
American Biogenetic Sciences, Inc. Jesup & Lamont Securities Corporation, “New Buy Recommendation dated Mar. 28, 1996” (12 pages.).
Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. “Cardiac-Specific Troponin I Levels To Predict The Risk Of Mortality In Patients With Acute Coronary Syndromes.”N. Eng. J. Med.1996; 335(18): 1342-1349.
AtheroGenics, Inc. Printout of Web Site (www.Atherogenics.com). Home page and “Technology Platform” and “In The News” sections. 17 pages (printed Jun. 8, 1998).
Aviram M, Maor I. “Phospholipase D-Modified Low Density Lipoprotein Is Taken Up By Macrophages At Increased Rate. A Possible Role For Phosphatidic Acid.”J. Clin. Invest.1993; 91: 1942-1952.
Berliner JA, Heinecke JW. “The Role Of Oxidized Lipoproteins In Atherogenesis,”Free Radical Biology&Medicine1996; 20(5): 707-727.
Brown MS, Goldstein JL. “Lipoprotein Metabolism In The Macrophage: Implications For Cholesterol Deposition In Atherosclerosis.”Annu. Review Biochem.1983; 52: 223-261.
Cartier
Collen Désiré J.
Holvoet Paul N.
Bryan Cave LLP
Gabel Gailene R.
Gilbert Stephen P.
Le Long V.
Leuven Research & Development VZW
LandOfFree
Detection and determination of the stages of coronary artery... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection and determination of the stages of coronary artery..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection and determination of the stages of coronary artery... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3747961